Free Articles, Free Web Content, Reprint Articles
Wednesday, October 21, 2020
 
Free Articles, Free Web Content, Reprint ArticlesRegisterAll CategoriesTop AuthorsSubmit Article (Article Submission)ContactSubscribe Free Articles, Free Web Content, Reprint Articles
 

China Biopharmaceutical Contract Manufacturing Market: Installed Capacity

Presently, the largest proportion (53%) of the overall biopharmaceutical manufacturing capacity is installed in facilities located in eastern China. This can be attributed to the fact that a large number of biopharmaceutical manufacturers are based in the aforementioned region. This is followed by the facilities based in northern China, where 18% of the overall capacity is installed.

 

Majority share (53%) of the biopharmaceutical contract manufacturing capacity in China is primarily driven by mid-sized companies. This can be attributed to relatively higher number of mid-sized players in the biopharmaceutical contract manufacturing market in China. Examples of Chinese biopharmaceutical contract manufacturers which were observed to have the highest capacity include (in decreasing order of capacity) WuXi AppTec, Asymchem, MabPlex, AutekBio, and GE Healthcare.

 

Over 80% of the current manufacturing capacity for biopharmaceutical in China is dedicated to commercial operations, while the remaining capacity is installed in companies operating at preclinical / clinical scales. This can be attributed to the growing number of expansion initiatives being carried out by several biopharmaceutical contract manufacturers in China to establish commercial scale manufacturing facilities.

 

Presently, the largest proportion (53%) of the overall biopharmaceutical manufacturing capacity is installed in facilities located in eastern China. This can be attributed to the fact that a large number of biopharmaceutical manufacturers are based in the aforementioned region. This is followed by the facilities based in northern China, where 18% of the overall capacity is installed.

 

Further, in northern China, eastern China, Hong Kong and Taiwan, majority (over 50%) of the capacity is occupied by large and very large companies. While in central China and southern China, majority of the capacity is installed in facilities of mid-sized players.

 

 

Currently, majority of the capacity in most of the regions of China is installed for carrying out commercial scale operations. It is worth highlighting that, in Hong Kong, 100% of the capacity is for preclinical / clinical scale of manufacturing, whereas in Taiwan, 100% capacity is dedicated to commercial scale production of biopharmaceuticals. Examples of CMOs having established facilities in Taiwan for carrying out commercial scale of manufacturing include (in alphabetical order) Adimmune, Amaran Biotechnology, EirGenixFree Articles, JHL Biotech Mycenax Biotech and ScinoPharm.

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR


Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.

 



Health
Business
Finance
Travel
Technology
Home Repair
Computers
Marketing
Autos
Family
Entertainment
Education
Law
Communication
Other
ECommerce
Sports
Home Business
Self Help
Internet
Partners


Page loaded in 0.438 seconds